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ABSTRACT
Objective: To determine and compare the antimicrobial susceptibility patterns of Vibrio
cholerae 01 strains, which were isolated in two cholera epidemics in 1997 and 1999 in Dar
es Salaam.
Methods: V. cholerae 01 strains isolated from patients with cholera in Dar es Salaam city
during 1997 (94 isolates) and 1999 (87 isolates) were stored on nutrient agar slants at room
temperature and antimicrobial susceptibility pattern was determined, using Kirby Bauer
method.
Setting: Department of Microbiology and Immunology, Muhimbili Medical Centre, Dar es
Salaam, Tanzania.
Results: A total of 181 V. cholerae 01 strains were studied during two epidemic periods when
tetracycline or erythromycin was used for treatment of patients with severe disease. Among
the 94 V. cholerae Ol strains isolated in 1997; 98.6%, 93.6%, 83%, 81.9%, 36.2%, 35.5%,
3.2% were sensitive to ciprofloxacin, tetracycline, ampicillin, erythromycin, nalidixic acid,
chloramphenicol and trimethoprim/ sulphamethoxazole, respectively. Among the 87 V.
cholerae 01 isolates collected in 1999, 100%, 58.6%, 46.0%, 46%, 47.1%, 19.5%, 3.4% were
sensitive to ciprofloxacin, tetracycline, ampicillin, erythromycin, chloramphenicol, nalidixic
acid and trimethoprim/sulphamethoxazole, respectively. Between 1997 and 1999, there was
a significant increase in the proportion of V. cholerae 01 isolates resistant to tetracycline,
ampicillin, nalidixic acid and to erythromycin but there was no change for susceptibility to
ciprofloxacin and trimethoprim/ sulphamethoxazole.
Conclusion: Significant proportion of V. cholerae 0l strains in Dar es Salaam were resistant
to commonly used antimicrobial agents during the two years of the study. Therefore, there
is a great need to control the utilisation of antimicrobial agents in cholera control, in addition
to continuing carrying out surveillance of antimicrobial resistance as a guide to choice of
antimicrobial treatment. Rotational use of the available drugs with regular monitoring of
susceptibility may contribute to continuing usefulness of such drugs.
INTRODUCTION
Vibrio cholerae (V. cholerae) 01 the causative
organism of cholera was first described by Robert Koch in
1883(1). Of recent, V. cholerae 0139 has also been
associated with severe forms of cholera(2). Notification
and surveillance systems of infectious diseases including
that caused by V. cholerae 01 in most developing countries
is lacking, but available epidemiological and clinical
evidence show that cholera is a public health problem(3).
Throughout history, V. cholerae 0l has caused repeated
epidemics in various areas of the world, especially in Asia,
the Middle East and Africa(3). The first recorded major
cholera epidemic in Tanzania during the twentieth century
was reported in 1974, followed by the next epidemic that
occurred in 1977, and since then, the disease has remained
endemic with sporadic epidemics occurring mainly during
the rainy seasons in areas with poor sanitation(4,5). Fluid
and electrolyte replacement is the main stay of treatment
of cholera patients, however, patients with severe disease
require antibiotic treatment to reduce the duration of
illness and reduce replacement fluid intake. Like most
bacteria of clinical and public health significance, V.
cholerae  01 is continuously becoming more resistant to
a variety of antimicrobial agents, necessitating use of
newer drugs which are more expensive and have more
adverse effects to patients.
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Spread of cholera epidemics worldwide has been
associated with the emergence of multiple drug resistance
among a large number of V. cholerae 01 strains(2,4,6).
Literature on the antibiotic susceptibility of cholera
organisms from most developing countries is patchy.
Worldwide, V. cholerae 01 strains resistant to tetracycline,
trimethoprim/sulphamethoxazole and ampicillin are
common(6-10). In many of these studies, the main reasons
for the rapid rise in antimicrobial resistance have been
extensive antimicrobial prophylaxis, unauthorised
dispensing and use of these agents in animal
husbandry(11,12).
In Tanzania, data collected during cholera epidemics
in 1990 and 1991 showed that all V. cholerae 01 strains
were sensitive to erythromycin, kanamycin, gentamicin
and ciprofloxacin(7). In a recent study on antimicrobial
susceptibility of V. cholerae 01 isolates from eastern
African countries between 1994 and 1996, about 80% to
90% of the isolates in Kenya and southern Sudan, and 65
to 90% of isolates in Somalia were sensitive to
tetracycline(9). However, during the same period, 100%
of isolates from Tanzania and Rwanda were resistant to
tetracycline(9) and the percentage of trimethoprim/
sulphamethoxazole and chloramphenicol sensitive strains
decreased from 85% to 10% during the same period(9). In
a recent study in India, most V. cholerae 01 isolates were
sensitive to tetracyline and gentamicin but were highly
resistant to trimethoprim/sulphamethoxazole(13 )
Antimicrobial resistance is therefore a global public
health problem. The increase in the magnitude of bacterial
species resistant to multiple antimicrobial agents have
shown linear relationship with the amount of antimicrobial
agents dispensed in a particular hospital or community for
treatment or prophylaxis (8, 9). We are reporting on the
comparison of the antimicrobial susceptibility patterns of
V. cholerae 01 isolates that were prevalent in the cholera
epidemics of 1997 and 1999 in Dar es Salaam city,
Tanzania.
MATERIALS AND METHODS
Study samples: The study was conducted at the Department
of Microbiology and Immunology,  Muhimbili Medical Centre,
which is the national referral hospital in Tanzania. The study
samples included V. cholerae 01 strains obtained from stool
samples submitted from patients treated in various hospitals in
Dar es Salaam, between May and June 1997 and between
January and May 1999 covering the main rainy season in the city.
The strains were stored on plain nutrient agar slants at room
temperature (22°C) with three monthly subculture and
subsequently subcultured on nutrient agar for antibiotic
susceptibility testing.
Laboratory methods: Stool samples were inoculated onto
Thiosulphate-Citrate-Bile-Salt (TCBS) agar, incubated at 37°C
for 24 hours. Suspected V. cholerae 01 isolates were identified
based on characteristic colonial morphology, motility, and
agglutination with specific V. c holerae polyvalent 01 and V.
cholerae serotype Ogawa and Inaba antisera. Non-agglutinating
characteristic colonial growth was subjected to biochemical tests
and if positive were named V. cholerae non-01 and were not
processed further. Outbreaks of V. cholerae 0139 have not yet
been described in East Africa in spite of continuing surveillance
for the organism.
Antimicrobial susceptibility testing was done using the
Kirby-Bauer method(14). Briefly, five colonies of V. cholerae
01 were lightly touched with a loop and inoculated in a tube
containing Muller Hinton broth and incubated for a few hours at
35°C until the suspension became slightly turbid and then diluted
with sterile saline to match the 0.5 Mac Farland turbidity standard
(1.5 x 105 colony forming units/ml). Using a sterile cotton swab,
an entire surface of dried Muller Hinton agar plate (15x 150 mm
Petri dish) with 4mm of agar depth was streaked uniformly with
the swab dipped in the standard V. cholerae suspension after
squeezing off extra fluid on the walls of the tube. The inoculated
plate was allowed to dry for about five minutes and the appropriate
antibiotic disks were then applied using sterile forceps and
incubated at 37°C overnight. The commercial antibiotic disks
used included: tetracycline (30 µg), chloramphenicol (30 µg),
erythromycin (15 µg), ampicillin (10 µg), nalidixic acid (30 µg),
trimethoprim/sulphamethoxazole (25 µg) and ciprofloxacin
(5 µg). After the incubation, the inhibition zone diameters were
measured using a transparent plastic ruler and compared with
those of a control organism (Escherichia coli NCTC 25922),
which was tested whenever a batch of V. cholerae 01 strains was
tested. The inhibition zones were interpreted according to zone
size by using a table that relates zone diameter to the degree of
microbial resistance(15). Isolates that were moderately sensitive
were taken as fully sensitive during analysis.
Data analysis: Proportions of the sensitive V. cholerae 01
isolated in 1997 and 1999 were compared using the Chi-squared
test, and a two-sided p value less than 0.05 was used to indicate
statistically significant differences.
RESULTS
A total of 181 V. cholerae 01 strains were studied
comprising of 94 isolates collected in 1997 and 87 isolates
collected in 1999. All patients came from the three districts
of Dar es Salaam: Kinondoni, Temeke, and Ilala.
Tetracycline or erythromycin was being used for treatment
of patients with severe disease during the study period but
no prophylaxis with these drugs was recommended at the
time.
Table 1 compares the antimicrobial susceptibility
patterns of the V. cholerae 01 isolates obtained in 1997 and
1999. Among the 1997 isolates, 73/74 (98.6%), 88/94
(93.6%), 78/94 (83%), 77/94 (81.9%), 34/94 (36.2), 33/94
(35.5%) and 3/94 (3.2%) were sensitive to ciprofloxacin,
tetracycline, ampicillin, erythromycin, chloramphenicol,
nalidixic acid and trimethoprim/sulphamethoxazole
respectively. Antimicrobial susceptibility patterns of the
V. cholerae 01 isolates collected in 1999 showed that, 86/
86 (100%), 51/87 (58.6%), 40/87 (46.0%), 40/87 (46%)
and 41/87 (47.1%) were sensitive to ciprofloxacin,
t e t r a c y c l i n e ,  a m p i c i l l i n ,  e r y t h r o m y c i n  a n d
chloramphenicol, respectively. Nevertheless, only 17/87
(19.5%) strains were sensitive to nalidixic acid while 3/94
(3.4%) isolates were sensitive to trimethoprim/
sulphamethoxazole.
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When the antimicrobial susceptibility patterns of the
V. cholerae 01 isolates obtained in 1997 were compared
with those in 1999, there was a significant increase in the
proportion of isolates resistant to tetracycline, ampicillin,
nalidixic acid and erythromycin and a sustained very high
resistance to trimethoprim/sulphamethoxazole. However,
there was no significant increase in the number of isolates
resistant to ciprofloxacin in the two years.
DISCUSSION
Globally, most bacterial pathogens are becoming
more resistant to commonly used antimicrobial agents.
Majority of cholera patients are usually treated by
replacement of fluids and electrolytes, and only a small
proportion with severe disease require antibiotic treatment.
In the present study, more than 93% of V. cholerae 01
strains isolated in Dar es Salaam in 1997 were sensitive to
tetracycline but two years later the number of tetracycline
resistant isolates had significantly increased by thirty five
per cent. Similar significant increase in resistant strains
was observed against ampicillin, nalidixic acid and
erythromycin during the same period. Treatment guidelines
given by the Ministry of Health in Tanzania discourage
giving prophylaxis for contacts of cholera patients,
therefore the significant increase in the proportion of V.
cholerae 01 resistant to tetracycline and erythromycin
which were being used to treat cholera patients could be
attributed to antibiotic pressure. Moreover, tetracycline
and trimethoprim/sulphamethoxazole may be among the
most commonly used drugs in the population for other
common infections. However, majority of the V. cholerae
01 strains during the study period in Dar es Salaam
remained sensitive to ciprofloxacin which was recently
introduced and is more expensive.
There have been several reports of V. cholerae 01
isolates resistant to multiple antimicrobial agents in the
African region including Tanzania(6-10). Clinical
observations have shown that when antibiotic pressure on
a given epidemic is reduced, resistant bacterial strains tend
to be replaced by sensitive ones (this observation is made
Table 1
Comparison of antimicrobial susceptibility patterns of V. cholerae 01 isolates collected in 1997 and 1999 to various antibiotics in Dar es Salaam
1997 1999
Antibiotic No No sensitive(%) No No sensitive(%) p value
Ciprofloxacin 74 73 (98.6) 86 86 (100) 0.67
Tetracycline 94 88 (93.6) 87 51 (58.6) <0.001
Ampicillin 94 78 (83.0) 87 40 (46.0) <0.001
Erythromycin 94 77 (81.9) 87 40 (46.0) <0.001
Chloramphenicol 94 33 (35.5) 87 41 (47.1) 0.100
Nalidixic acid 94 34 (36.2) 87 17 (19.5) 0.013
Trimethoprim/
sulphamethoxazole 94 3 (3.2) 87 3 (3.4) 0.753
by one of the authors, FSM). The current study has shown
a significant increase in the percentage of V. cholerae 01
isolates resistant to antimicrobial agents, some of which
are extensively used in Tanzania in agreement with other
published reports(8-11). Worldwide, there is great variation
in the distribution of antibiotic resistant V. cholerae 01
strains(3,11,12,17). Our results suggest that the
antimicrobial susceptibility patterns of V. cholerae 01
cannot be predicted easily. In Tanzania, like in many other
developing countries, there is no control in the prescription
of antimicrobial agents and that antibiotics are also widely
used in animal husbandry, which may account for the
problem of increasing spread of antimicrobial resistance.
In conclusion, a significant proportion of V. cholerae
01 isolates in Dar es Salaam are becoming resistant to
commonly used antimicrobial agents over time. Of utmost
importance is the need to establish regular nationwide
antibiotic susceptibility surveillance of V. cholerae 01 in
different parts of the country in order to provide guidance
on the best options in different situations. From this study,
it is clear that rotational use of anti-cholera antibiotics may
lead to emergence of fully susceptible strains over time,
which may allow for extension of use of the most effective
therapies such as tetracycline.
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